Multimodal therapies for muscle-invasive urothelial carcinoma of the bladder

Current Opinion in Oncology

Volumn 24, Issue 3, 2012, Pages 278-283

  Keegan, Kirk A ^a   Resnick, Matthew J ^a   Clark, Peter E ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

bladder cancer; chemotherapy; multimodal therapy; radiation; review

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; METHOTREXATE; PACLITAXEL; VINBLASTINE;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BLADDER CARCINOMA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INVASION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; COLIC; CYSTECTOMY; DIARRHEA; DISEASE SPECIFIC SURVIVAL; DYSURIA; HUMAN; MULTIPLE CYCLE TREATMENT; ORGAN PRESERVATION; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION DOSE; REVIEW; RISK ASSESSMENT; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; TREATMENT RESPONSE; UROGENITAL TRACT DISEASE;

ANTINEOPLASTIC AGENTS; CARCINOMA, TRANSITIONAL CELL; CHEMOTHERAPY, ADJUVANT; CYSTECTOMY; FEMALE; HUMANS; MALE; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE; UNITED STATES; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 84859865780     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3283510587     Document Type: Review

References (44)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61:212-236.
2. Wein AJ, Louis R, Kavoussi MD, et al. Campbell-Walsh urology. Philadelphia: W B Saunders Co; 2011.
3. Scardino PT, Linehan WM, Zelefsky MJ, et al. editors. Comprehensive textbook of genitourinary oncology. Philadelphia: Lippincott Williams & Wilkins; 2011.
4. Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet 2009; 374:239-249.
5. Rübben H, Lutzeyer W, Fischer N, et al. Natural history and treatment of low and high risk superficial bladder tumors. J Urol 1988; 139:283-285.
6. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients. J Clin Oncol 2001; 19:666-675. (Pubitemid 32120143)
7. Madersbacher S, Hochreiter W, Burkhard F, et al. Radical cystectomy for bladder cancer today-a homogeneous series without neoadjuvant therapy. J Clin Oncol 2003; 21:690-696. (Pubitemid 46621904)
8. Yafi FA, Aprikian AG, Chin JL, et al. Contemporary outcomes of 2287 patients with bladder cancer who were treated with radical cystectomy: a Canadian multicentre experience. BJU Int 2011; 108:539-545.
9. Dalbagni G, Genega E, Hashibe M, et al. Cystectomy for bladder cancer: a contemporary series. J Urol 2001; 165:1111-1116. (Pubitemid 32210214)
10. International Collaboration of Trialists, Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group), European Organisation for Research and Treatment of Cancer GenitoUrinary Tract Cancer Group, Australian Bladder Cancer Study Group, National Cancer Institute of Canada Clinical Trials Group, Finnbladder, Norwegian Bladder Cancer Study Group, Club Urologico Espanol de Tratamiento Oncologico Group, Griffiths G, Hall R, et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 2011; 29:2171-2177.
11. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003; 349:859-866. (Pubitemid 37025405)
12. Sherif A, Holmberg L, Rintala E, et al. Nordic Urothelial Cancer Group: Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. Eur Urol 2004; 45:297-303. (Pubitemid 38221402)
13. Fedeli U, Fedewa SA, Ward EM. Treatment of muscle invasive bladder cancer: evidence from the National Cancer Database; 2003 to 2007. J Urol 2011; 185:72-78.
14. Miles BJW, Fairey AS, Eliasziw M, et al. Referral and treatment rates of neoadjuvant chemotherapy in muscle-invasive bladder cancer before and after publication of a clinical practice guideline. Can Urol Assoc J 2010; 4:263-267.
15. Raj GV, Karavadia S, Schlomer B, et al. Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer. Cancer 2011; 117:276-282.
16. Feifer AH, Taylor JM, Tarin TV, Herr HW. Maximizing cure for muscle-invasive bladder cancer: integration of surgery and chemotherapy. Eur Urol 2011; 59:978-984.
17. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and metaanalysis of individual patient data Advanced Bladder Cancer (ABC) Metaanalysis Collaboration. Eur Urol 2005; 48:189-199; discussion 199-201.
18. Svatek RS, Shariat SF, Lasky RE, et al. The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. Clin Cancer Res 2010; 16:4461-4467.
19. Donat SM, Shabsigh A, Savage C, et al. Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. Eur Urol 2009; 55:177-185.
20. Stimson CJ, Chang SS, Barocas DA, et al. Early and late perioperative outcomes following radical cystectomy: 90-day readmissions, morbidity and mortality in a contemporary series. J Urol 2010; 184: 1296-1300.
21. Millikan R, Dinney C, Swanson D, et al. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol 2001; 19:4005-4013. (Pubitemid 32976686)
22. Fernando SA, Sandler HM. Multimodality bladder preservation therapy for muscle-invasive bladder tumors. Semin Oncol 2007; 34:129-134. (Pubitemid 46436118)
23. Balar A, Bajorin DF, Milowsky MI. Management of invasive bladder cancer in patients who are not candidates for or decline cystectomy. Ther Adv Urol 2011; 3:107-117.
24. Herr HW, Cookson MS, Soloway SM. Upper tract tumors in patients with primary bladder cancer followed for 15 years. J Urol 1996; 156: 1286-1287. (Pubitemid 26307595)
25. Shipley WU, Winter KA, Kaufman DS, et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy and Oncology Group 89-03. J Clin Oncol 1998; 16:3576-3583. (Pubitemid 28506771)
26. Shipley WU, Kaufman DS, Zehr E, et al. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology 2002; 60: 62-68.
27. Houseset M, Maulard C, Chretien Y, et al. Combined radiation and chemotherapy for invasive transitional cell carcinoma of the bladder: a prospective study. J Clin Oncol 1993; 1:2150-2157. (Pubitemid 23332251)
28. Herr HW, Bajorin DF, Scher HI. Neoadjuvant chemotherapy and bladdersparing surgery for invasive bladder cancer: ten-year outcome. J Clin Oncol 1998; 16:1298-1301. (Pubitemid 28175743)
29. DeVere White RW, Lara Jr, PN, Goldman B, et al. A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219). J Urol 2009; 181:2476-2480.
30. Koga F, Kihara K, Yoshida S, et al. Selective bladder-sparing protocol consisting of induction low-dose chemoradiotherapy plus partial cystectomy with pelvic lymph node dissection against muscle-invasive bladder cancer: oncological outcomes of the initial 46 patients. BJU Int 2011 [Epub ahead of print].
31. Rodel C, Grabenbauer GG, Kuhn R, et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 2002; 20:3061-3071. (Pubitemid 34791095)
32. Seiwert TY, Salama JK, Vokes EE. The concurrent chemoradiation paradigm-general principles. Nat Clin Pract Oncol 2007; 4:86-100.
33. Shipley W, Zietman A, Kaufman D, et al. Selective bladder preservation by trimodality therapy for patients with muscularis propria invasive bladder cancer and who are cystectomy candidates-The Massachusetts General Hospital and Radiation Therapy Group experiences. Semin Radiat Oncol 2004; 15:36-41. (Pubitemid 40127277)
34. Tester W, Porter A, Asbell S, et al. Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG 85-12. Int J Radiat Oncol Biol Phys 1993; 25:783-790. (Pubitemid 23123381)
35. Kaufman DS, Winter KA, Shipley WU, et al. The initial results in muscle invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-FU followed by selective bladder preservation or cystectomy depending on the initial response. Oncologist 2000; 5:471-476.
36. Kaufman DS, Winter KA, Shipley WU, et al. Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. Urology 2009; 73:833-837.
37. Caffo O, Fellin G, Graffer U, et al. Gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer: long-term cumulative results of 2 prospective single-institution studies. Cancer 2011; 117:1190-1196.
38. Pieras E, Palou J, Salvador J, et al. Management and prognosis of transitional cell carcinoma. Superficial recurrence in muscle invasive bladder cancer after bladder preservation. Eur Urol 2003; 44:222-225. (Pubitemid 36917007)
39. Zietman AL, Grocela J, Zehr E, et al. Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder. Urology 2001; 58:380-385. (Pubitemid 32816355)
40. Zietman AL, Sacco D, Skowronski U, et al. Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors. J Urol 2003; 170:1772-1776. (Pubitemid 37254925)
41. Efstathiou JA, Bae K, Shipley WU, et al. Late pelvic toxicity after bladdersparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06. J Clin Oncol 2009; 27:4055-4061.
42. Ginsburg GS, Willard HF. Genomic and personalized medicine: foundations and applications. Transl Res 2009; 154:277-287.
43. Smith SC, Baras AS, Dancik G, et al. A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment. Lancet Oncol 2011; 12:137-143.
44. Shah JB, McConkey DJ, Dinney CPN. New strategies in muscle-invasive bladder cancer: on the road to personalized medicine. Clin Cancer Res 2011; 17:2608-2612.